Author(s): Masih Falahatian *, Ahmad Chitsaz
Alzheimer's disease is a neurodegenerative disease, which usually helps
some biomarkers, such as amyloid proteins, to diagnose the disease. Therefore, the
purpose of this study was to compare the expression of a protein binding protein to the
adjuvant responder to circular adenosine monophosphate (CREB) in peripheral blood
of patients to Alzheimer's and healthy elderly people as a biomarker for diagnosing
Alzheimer.
Materials and Methods:
In this case-control study, 32 patients with
Alzheimer's disease and 32 normal blood samples were taken. Using real time PCR,
CREB expression was evaluated.
Results:
The mean CREB level in the case group was
0.89 ± 0.30 and in the control group was 1.01 ± 0.03. The mean of BDNF level in the
case group was significantly higher than the control group (P <0.001). There was no
significant relationship between the level of CREB with age, sex, MMSE score and
Cornell scale for depression in dementia (P> 0.05).
Conclusion:
Reducing CREB
levels in people with Alzheimer's disease can be a factor in diagnosis in comparison to
healthy people.